Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (4): 680-685. doi: 10.19723/j.issn.1671-167X.2022.04.016

Previous Articles     Next Articles

Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma

Min QIU1,Yan-yan LIAN2,Min LU3,Bin-shuai WANG1,Xiao-jun TIAN1,Jian LU1,Cheng LIU1,*(),Shu-dong ZHANG1,Min JIANG4,Lu-lin MA1,*()   

  1. 1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
    2. The Third Clinical Medical College of Beijing University of Chinese Medicine, Beijing 100029, China
    3. Department of Pathology, Peking University Third Hospital, Beijing 100191, China
    4. Department of Oncology, Dong Fang Hospital of Beijing University of Chinese Medicine, Beijing 100078, China
  • Received:2022-03-31 Online:2022-08-18 Published:2022-08-11
  • Contact: Cheng LIU,Lu-lin MA E-mail:chengliu@bjmu.edu.cn;malulin@bjmu.edu.cn

RICH HTML

   

PDF (PC)

Abstract:

Objective: To investigate the treatment and prognosis of multiple primary malignant neoplasms (MPMN) complicated with renal cell carcinoma (RCC), and to make risk stratification. Methods: A retrospective study of 27 cases of MPMN with RCC in two centers, including the different tumors of MPMN, specific treatment methods, and the interval between primary cancers. At the same time, the survival conditions, including recurrence, metastasis and survival, were followed up for statistical analysis. The interval between the two kinds of primary cancer within 6 months was simultaneous MPMNs, and more than 6 months was metachronous MPMNs. For simple risk stratification of cases, as long as one of the MPMNs had a stage Ⅲ or higher malignancy, which was defined as high risk. Results: Among the 27 patients, 20 were male and 7 were female, with age at the time of diagnosis was 42-82 years, with an average age of (61.3±11.7) years. The age at the diagnosis of renal cancer was 43-87 years, with an average age of (66.0±11.3) years. There were 21 cases with duplex primary malignant neoplasms, 4 cases with triple primary malignant neoplasms, and 2 cases with quadruple primary malignant neoplasms. The interval between first cancer and second cancer was 0-360 months, with a median of 18 months. There were 17 cases of metachronous multiple primary malignant neoplasms and 10 cases of simultaneous multiple primary malignant neoplasms. The most common system of MPMN with comorbid RCC involved urologic system, digestive system and respiratory system. The most common locations of MPMN with comorbid RCC were bladder cancer, lung cancer and colon cancer. Follow-up time calcu- lated from the last cancer was 2-156 months, with a median of 32 months. And 14 cases survived and 13 cases died, with 11 cases being tumor related. Tumor stage was the risk factor of prognosis. Any kind of tumor stage in stage Ⅲ or above had a relatively poor prognosis. Conclusion: MPMN complicated with RCC is relatively rare. Standard treatment should be used for each cancer type during the treatment process. The prognosis mainly depends on the highest stage of each tumor. Simple risk stratification shows that the prognosis of the high-risk group is worse. This simple stratification method may be helpful to predict the prognosis.

Key words: Neoplasms, multiple primary, Neoplasms, second primary, Carcinoma, renal cell, Prognosis

CLC Number: 

  • R737.11

Table 1

Clinical data of the patients with MPMN"

No. Gender Age/years FPC/Stage IT/months SPC/Stage IT/months TPC/Stage IT/months FOPC/Stage Follow up time/months Outcome
1 F 49 THCA/Ⅰ 110 RCC/Ⅰ 113 Survival
2 M 59 COAD/Ⅱ 2 RCC/Ⅰ 4 Survival
3 F 64 STAD/Ⅲ 1 RCC/Ⅰ 62 Survival
4 M 60 READ/Ⅳ 6 RCC/Ⅰ 22 Death
5 M 79 RCC/Ⅲ 45 NONB/Ⅰ 60 Survival
6 M 56 LUAD/Ⅱ 5 RCC/Ⅰ 48 Survival
7 M 66 RCC/Ⅰ 7 BCC/Ⅰ 28 Survival
8 M 87 BLCA 264 RCC/Ⅰ 420 Death
9 M 77 BLCA 360 RCC/Ⅰ 408 Death
10 M 72 RCC/Ⅰ 73 COAD/Ⅰ 111 Survival
11 M 42 NPC/Ⅳ 26 RCC/Ⅰ 34 Death
12 M 46 BLCA/Ⅰ 18 RCC/Ⅰ 92 Survival
13 M 64 RCC/Ⅰ 0 BLCA/Ⅰ 52 Survival
14 M 82 BLCA/Ⅰ 0 RCC/Ⅰ 48 Survival
15 M 66 BLCA/Ⅰ 21 RCC/Ⅰ 12 COAD/Ⅰ 70 Survival
16 M 57 NHL/Ⅱ 3 RCC/Ⅰ 3 PC/Ⅱ 84 Survival
17 F 70 BC/Ⅱ 24 LUAD/Ⅰ 12 RCC/Ⅰ 16 NHL/Ⅰ 75 Survival
18 M 77 LE 276 BLCA/Ⅰ 93 RCC/Ⅰ 2 EC/Ⅲ 432 Death
19 M 43 LUAD/Ⅳ 0 RCC/Ⅱ 11 Death
20 M 70 STAD/Ⅱ 1 RCC/Ⅱ 134 Death
21 M 82 LUAD/Ⅲ 0 RCC/Ⅱ 25 Death
22 M 61 COAD/Ⅳ 4 RCC/Ⅱ 31 Death
23 M 66 RCC/Ⅲ 98 LUAD/Ⅲ 122 Death
24 F 61 RCC/Ⅱ 235 LUAD/Ⅳ 237 Death
25 F 61 RCC/Ⅱ 44 HL/Ⅳ 89 Survival
26 F 45 BC/Ⅱ 348 STAD/Ⅳ 1 RCC/Ⅱ 360 Death
27 F 75 RCC/Ⅱ 12 UC/Ⅲ 0 BLCA/Ⅳ 44 Death

Figure 1

Survival curve of different risk stratification Group 1 for low-risk group, and Group 2 for high-risk group. The estimated median survival time is 133 months in low-risk group and 25 months in high-risk group."

Figure 2

Survival curve of different centers The estimated median survival time was 156 months in center 1 and 25 months in center 2."

1 Matzkin H , Braf Z . Multiple primary malignant neoplasms in the genitourinary tract: Occurrence and etiology[J]. J Urol, 1989, 142 (1): 1- 12.
doi: 10.1016/S0022-5347(17)38649-4
2 宋航, 邱敏, 卢剑, 等. 合并肾癌的多原发癌诊断与治疗[J]. 北京大学学报(医学版), 2016, 48 (5): 926- 929.
doi: 10.3969/j.issn.1671-167X.2016.05.034
3 Warren S , Gates O . Multiple primary malignant tumor A surgery of the literature and statistical study[J]. Am J Cancer, 1932, 51 (16): 1358- 1414.
4 Moertel CG , Dockerty MB , Baggenstoss AH . Multiple primary malignant neoplasms. Ⅰ. Introduction and presentation of data[J]. Cancer, 1961, 14, 221- 230.
doi: 10.1002/1097-0142(196103/04)14:2<221::AID-CNCR2820140202>3.0.CO;2-6
5 Feller A , Matthes KL , Bordoni A , et al. The relative risk of second primary cancers in Switzerland: A population-based retrospective cohort study[J]. BMC Cancer, 2020, 20 (1): 51- 65.
doi: 10.1186/s12885-019-6452-0
6 Tanjak P , Suktitipat B , Vorasan N , et al. Risks and cancer associations of metachronous and synchronous multiple primary can-cers: A 25-year retrospective study[J]. BMC Cancer, 2021, 21 (1): 1045- 1054.
doi: 10.1186/s12885-021-08766-9
7 El-Taji O , Al-Mitwalli A , Malik F , et al. Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes[J]. Transl Androl Urol, 2021, 10 (6): 2427- 2434.
doi: 10.21037/tau-20-955
8 Beisland C , Talleraas O , Bakke A , et al. Multiple primary malignancies in patients with renal cell carcinoma: A national population-based cohort study[J]. BJU Int, 2006, 97 (4): 698- 702.
doi: 10.1111/j.1464-410X.2006.06004.x
9 Koh HM , An HJ , Ko GH , et al. Identification of myoferlin expression for prediction of subsequent primary malignancy in patients with clear cell renal cell carcinoma[J]. In Vivo, 2019, 33 (4): 1103- 1108.
doi: 10.21873/invivo.11579
10 Tian X , Xu WH , Wu JL , et al. Clear cell papillary renal cell carcinoma shares distinct molecular characteristics and may be significantly associated with higher risk of developing second primary malignancy[J]. Pathol Oncol Res, 2021, 27, 1609809.
doi: 10.3389/pore.2021.1609809
11 邱敏, 卢剑, 马潞林, 等. 透明细胞乳头状肾细胞癌的诊治经验[J]. 中华泌尿外科杂志, 2016, 37 (9): 655- 659.
doi: 10.3760/cma.j.issn.1000-6702.2016.09.004
12 Heo J , Noh O K , Oh Y , et al. Second primary cancer after liver transplantation in hepatocellular carcinoma: A nationwide population-based study[J]. Hepatol Int, 2017, 11 (6): 523- 528.
doi: 10.1007/s12072-017-9824-z
13 Wang L , Wang H , Wang T , et al. Analysis of polymorphisms in genes associated with the FA/BRCA pathway in three patients with multiple primary malignant neoplasms[J]. Artif Cells Nanomed Biotechnol, 2019, 47 (1): 1101- 1112.
doi: 10.1080/21691401.2019.1575846
14 Peng L , Zeng Z , Teng X , et al. Genomic profiling of synchronous triple primary tumors of the lung, thyroid and kidney in a young female patient: A case report[J]. Oncol lett, 2018, 16 (5): 6089- 6094.
15 Keegan THM , Bleyer A , Rosenberg AS , et al. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors[J]. JAMA Oncology, 2017, 3 (11): 1554- 1557.
doi: 10.1001/jamaoncol.2017.0465
16 Cho YY , Lim J , Oh C , et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea[J]. Cancer, 2015, 121 (2): 259- 268.
doi: 10.1002/cncr.29025
17 Joung JY , Kwon W , Lim J , et al. Second primary cancer risk among kidney cancer patients in Korea: A population-based cohort study[J]. Cancer Res Treat, 2018, 50 (1): 293- 301.
doi: 10.4143/crt.2016.543
18 Etiz D , Metcalfe E , Akcay M . Multiple primary malignant neoplasms: A 10-year experience at a single institution from Turkey[J]. J Cancer Res Ther, 2017, 13 (1): 16- 20.
[1] Lingfu ZHANG, Ming CHEN, Xiaoyu ZHAO, Gang WANG, Long CUI, Xiaofeng LING, Lixin WANG, Zhi XU, Limei GUO, Chunsheng HOU. Gross classification of gallbladder cancer with primary lesion limited to the gallbladder wall and its correlation with prognosis and precancerous lesions [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 184-189.
[2] Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649.
[3] Weihao LI, Jing LI, Xuemin ZHANG, Wei LI, Qingle LI, Xiaoming ZHANG. Effect of intraoperative blood salvage autotransfusion on the prognosis of patients after carotid body tumor resection [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 272-276.
[4] Yaqing MAO, Zhen CHEN, Yao YU, Wenbo ZHANG, Yang LIU, Xin PENG. Impact of type 2 diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1089-1096.
[5] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[6] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[7] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[8] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[9] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[10] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[11] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[12] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[13] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[14] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[15] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd